Eisai To Manufacture Breast Cancer Drug In Europe
This article was originally published in PharmAsia News
Executive Summary
Eisai announced June 26 a ¥5 billion additional investment to European Knowledge Center in Hatfield, a suburb of London. The company completed and opened the facility the same day. Eisai plans to manufacture breast cancer drug E7389 starting in 2011. Currently under Phase II trials in Japan and Phase III trials in the U.S. and Europe, Eisai aims for a 2010 NDA submission. Eisai previously invested ¥160 million to the center; the production line has an annual capacity of 400 million tablets. Positioned as a global strategic product for Eisai, E7389 is estimated to become a ¥100 billion blockbuster drug. (Click here for more - Japanese language
You may also be interested in...
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.